Objective: To identify a functionalmonoclonalantibody1E2 against lung cancer and itsantigen, so as to provide a candidateantibody drugandmoleculetarget for the anti-lung cancer therapy.
Now into this gloom comes a new type of drug, called an anti-CD3 antibody, that aims for the first time to delay or prevent development of the devastating disease by arresting the immune system's attack on pancreatic islet cells.